Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States

Sexually Transmitted Diseases

Volumn 29, Issue 10, 2002, Pages 608-622

  Fisman, David N ^a   Lipsitch, Marc ^a   Hook III, Edward W ^a   Goldie, Sue J ^a  

^a Hamilton Dept of Social Services   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COST OF ILLNESS; ECONOMIC ASPECT; EPIDEMIC; FEMALE; GENITAL HERPES; HEALTH SURVEY; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HUMAN; INFECTION CONTROL; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL LITERATURE; PREDICTION; PROBABILITY; PUBLIC HEALTH; SEROPREVALENCE; UNITED STATES; VIRUS TRANSMISSION;

EID: 0036792664     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200210000-00008     Document Type: Article

References (96)

1. Corey L, Handsfield H. Genital herpes and public health: addressing a global problem. JAMA 2000; 283:791-794.
2. Corey L, Wald A. Genital herpes. In: Holmes K, Mardh P, Wasserheit J, eds. Sexually Transmitted Diseases. 3rd ed. New York: McGraw-Hill, 1999:285-312.
3. Johnson R, Nahmias A, Magder L, Lee F, Brooks C, Snowden M. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321:7-12.
4. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111.
5. Langenberg A, Corey L, Ashley R, Leong W, Straus S. A prospective study of new infections with herpes simplex virus type 1 and type 2. N Engl J Med 1999; 341:1432-1438.
6. Wald A, Zeh J, Selke S, Ashley R, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-775.
7. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989; 110:882-887.
8. Corey L, Fife K, Benedetti J, et al. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 1983; 98:914-921.
9. Diamond C, Selke S, Ashley R, Benedetti J, Corey L. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis 1998; 26:221-225.
10. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 212:847-854.
11. Brown Z, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991; 324:1247-1252.
12. Brown Z, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509-515.
13. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis Suppl 1996; 100:27-32.
14. Carney O, Ross E, Ikkos G, Mindel A. The effect of suppressive oral acyclovir therapy on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993; 69:457-459.
15. Mertz G, Coombs R, Ashley R, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis 1988; 157:1168-1177.
16. Wald A, Selke S, Lowens S, et al. Sexual transmission of genital HSV: risk factors in a time-to-event analysis [abstract]. In: Zenilman J, ed. STIs at the Millennium: Past, Present, and Future. Baltimore: American Sexually Transmitted Diseases Association-Medical Society for the Study of Venereal Diseases, 2000.
17. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662-667.
18. Ashley R, Wald A, Eagleton M. Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culture-documented cases of genital herpes simplex virus type 2. Sex Transm Dis 2000; 27:266-269.
19. Kennedy M, Mizuno Y, Seals B, Myllyluoma J, Weeks-Norton K. Increasing condom use among adolescents with coalition based social marketing. AIDS 2000; 14:1809-1818.
20. Cohen D, Farley T, Bedimo-Etame J, et al. Implementation of condom social marketing in Louisiana, 1993 to 1996. Am J Public Health 1999; 89:204-208.
21. Blower SM, Gershengorn HB, Gaff H, Wald A. Chronic suppressive therapy as an epidemic control agent for herpes simplex virus type 2 (HSV-2) epidemics [abstract]. In: Zenilman J, ed. STIs at the Millennium: Past, Present, and Future. Baltimore: American Sexually Transmitted Diseases Association-Medical Society for the Study of Venereal Diseases, 2000.
22. Wald A, Zeh J, Barnum G, Davis L, Corey L. Suppression of subclinical shedding of herpes simple virus type 2 with acyclovir. Ann Intern Med 1996; 124:8-15.
23. Stanberry L, Cunningham A, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000; 30:549-566.
24. Hickling JK, Roberts JSC, Uttridge JA, et al. Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in HSV-2 seropositive and seronegative subjects [abstract]. In: Zenilman J, ed. STIs at the Millennium: Past, Present, and Future. Baltimore: American Sexually Transmitted Diseases Association-Medical Society for the Study of Venereal Diseases, 2000.
25. Anderson R. Transmission dynamics of sexually transmitted infections. In: Holmes K, Sparling P, Mardh P, et al., eds. Sexually Transmitted Diseases. New York: McGraw-Hill, 1999.
26. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
27. US Census Bureau. Statistical Abstract of the United States: 1999. 119th ed. Washington, DC: Department of Commerce, 1999.
28. Mertz G, Benedetti J, Ashley R, Selke S, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116: 197-202.
29. Bryson Y, Dillon M, Bernstein D, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993; 167:942-946.
30. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282:331-340.
31. Centers for Disease Control and Prevention, Division of STD Prevention. Sexually Transmitted Diseases Surveillance, 1999. Atlanta: Centers for Disease Control and Prevention, 2000. Available at: http://www.cdc.gov/nchstp/dstd/Stats_Trends/1999Surveillance/ 99PDF/Surv99Master.pdf.
32. Benedetti J, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131:14-20.
33. Whitley R. Neonatal herpes simplex virus infections. J Med Virol 1993; suppl 1:13-21.
34. Whitley R. Herpes simplex virus infections of women and their offspring: implications for a developed society. Proc Natl Acad Sci USA 1994; 91:2441-2447.
35. Randolph A, Washington A, Prober C. Cesarean delivery for women presenting with genital herpes lesions: efficacy, risks, and costs. JAMA 1993; 270:77-81.
36. Lahat E, Barr J, Barkai G, Paret G, Brand N, Barzilai. Long term neurological outcome of herpes encephalitis. Arch Dis Child 1999; 80:69-71.
37. Randolph A, Hartshorn R, Washington A. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol 1996; 88:603-610.
38. Tao G, Kassler W, Rein D. Medical care expenditures for genital herpes in the United States. Sex Transm Dis 2000; 27:32-38.
39. Oruc S, Esen A, Lacin S, Adiguzel H, Uyar Y, Koynucu F. Sexual behavior during pregnancy. Aust NZ J Obstet Gynecol 1999; 39: 48-50.
40. Bogren L. Changes in sexuality in women and men during pregnancy. Arch Sex Behav 1991; 20:35-45.
41. Elliott S, Watson J. Sex during pregnancy and the first postnatal year. J Psychosom Res 1985; 29:541-548.
42. Bujko M, Sulovic V, Zivanovic V, Dotlic R, Bardic I. Herpes simplex virus infection in women with previous spontaneous abortion. J Perinat Med 1988; 16:193-196.
43. Nahmias A, Josey W, Naib Z, Freeman M, Fernandez R, Wheeler J. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol 1971; 110:825-837.
44. Robb J, Benirschke K, Barmeyer R. Intrauterine latent herpes simplex virus infection: I. Spontaneous abortion. Hum Pathol 1986; 17: 1196-1209.
45. Brown Z, Vontver L, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med 1987; 317:1246-1251.
46. Prober C, Sullender W, Yasukawa L, Au D, Yeager A, Arvin A. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med 1987; 316:240-244.
47. Prober C, Corey L, Brown Z, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992; 15:1031-1038.
48. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998; 47(no. RR-1):1-128.
49. American College of Obstetrics and Gynecology. Management of herpes in pregnancy. Int J Gynaecol Obstet 2000; 68:165-173.
50. Brocklehurst P, Carney O, Ross E, Mindel A. The management of recurrent genital herpes infection in pregnancy: a postal survey of obstetric practice. Br J Obstet Gynaecol 1995; 102:791-797.
51. Marks C, Fethers K, Mindel A. Management of women with recurrent genital herpes in pregnancy in Australia. Sex Transm Infect 1999; 75:55-57.
52. Cardinale V, ed. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, 1997.
53. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med 1991; 324:450-454.
54. Whitley R, Arvin A, Prober C, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 1991; 324:444-449.
55. Waitzman N, Romano P, Schleffer R. Estimates of the economic costs of birth defects. Inquiry 1994; 31:188-205.
56. Bureau of Labor Statistics. Selective Data. Washington, DC: US Department of Labor, 1999. Available at: http://stats.bls.gov.80/ sahome.html.
57. Gold M, Patrick D, Torrance G, et al. Identifying and valuing outcomes. In: Gold M, Siegel J, Russell L, Weinstein M, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996:86-123.
58. Sullivan-Boylai J, Hull H, Wilson C, Corey L. Neonatal herpes simplex virus infection in King County, Washington. JAMA 1983; 250:3059-3062.
59. Bregman D, Langmuir A. Farr's law applied to AIDS projections. JAMA 1990; 263:1522-1525.
60. Armstrong G, Schillinger J, Markowitz L, et al. Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001; 153:912-920.
61. McQuillan GM. Implications of a national survey for STDs: results from NHANES survey [abstract]. In: Relman D, ed. Infectious Disease Society of America 38th Annual Meeting, 2000, New Orleans, LA. Alexandria, Virginia: Infectious Disease Society of America, 2000.
62. Sonenstein F, Ku L, Lindberg L, Turner C, Pleck J. Changes in sexual behavior and condom use among teenage males: 1988 to 1995. Am J Public Health 1998; 88:956-959.
63. Bankole A, Darroch J, Singh S. Determinants of trends in condom use in the United States. Fam Plann Perspect 1999; 31:264-271.
64. Santelli J, Lindberg L, Abma J, McNeely C, Resnick M. Adolescent sexual behavior: estimates and trends from four nationally representative surveys. Fam Plann Perspect 2000; 32:156-165.
65. Centers for Disease Control and Prevention. Increases in unsafe sex and rectal gonorrhea among men who have sex with men: San Francisco, California, 1994-1997. MMWR Morb Mortal Wkly Rep 1999; 40:45-48.
66. Wolitski R, Valdiserri R, Denning P, Levine W. Are we headed for a resurgence in the HIV epidemic among men who have sex with men? Am J Public Health 2001; 91:883-888.
67. Centers for Disease Control and Prevention. Resurgent bacterial sexually transmitted diseases among men who have sex with men. MMWR Morb Mortal Wkly Rep 1999; 48:773-777.
68. Brown W. Syphilis and Other Venereal Diseases. Cambridge: Harvard University Press, 1970.
69. Quetel C. History of Syphilis. Baltimore: Johns Hopkins University Press, 1990.
70. Gutierrez K, Falkovitz-Halpern M, Maldonado Y, Arvin A. The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. J Infect Dis 1999; 188:199-202.
71. Corey L, Adams H, Brown Z, Holmes K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958-972.
72. Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press, 1997.
73. Siegal J. The economic burden of sexually transmitted disease in the United States. In: Holmes K, Sparling P, Mardh P, et al. Sexually Transmitted Diseases. 3rd ed. New York: McGraw-Hill, 1999:1367-1379.
74. Szucs T, Berger K, Fisman D, Harbarth S. The estimated economic burden of genital herpes in the United States: an analysis using two costing approaches. BMC Infect Dis 2001; 1:5. Available at: http:// www.biomedcentral.com/1471-2334/1/5.
75. Fleming D, Wasserheit J. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
76. Chesson H, Pinkerton S. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr Hum Retrovirol 2000; 28:48-56.
77. Gaff H, Wald A, Blower S. Quantifying the impact of HSV-2 epidemics on increasing HIV transmission [abstract]. In: Zenilman J, ed. STIs at the Millenium: Past, Present, and Future. Baltimore: American Sexually Transmitted Diseases Association-Medical Society for the Study of Venereal Diseases, 2000.
78. Tolley G, Kenkel D, Fabian R. State-of-the-art health values. In: Tolley G, Kenkel D, Fabian R, eds. Valuing Health for Policy: An Economic Approach. Chicago: University of Chicago Press, 1994: 323-344.
79. Viramontes J, O'Brien B. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making 1994; 14: 289-297.
80. Jury awards ex-wife damages in herpes suit. New York Times. April 9, 1995:60.
81. Farabaugh M. Woman sues ex-lover over herpes infection. Baltimore Sun. March 27, 1994:8B.
82. Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation. Sex Transm Dis 1999; 26:250-261.
83. Aral SO, Hughes JP, Stoner B, et al. Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Am J Public Health 1999; 89:825-833.
84. Ashley R, Wu L, Picketing J. Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol 1998; 36:294-295.
85. Ashley R, Eagleton M, Pfeiffer N: Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. J Clin Microbiol 1999; 37:1632-1633.
86. Handsfield H, Stone K, Graber J. Report of the Genital Herpes Prevention Consultants Meeting, May 5-6, 1998. Atlanta: Centers for Disease Control and Prevention, 1998:1-10.
87. Spruance S. Gender-specific efficacy of a prophylactic SBAS4-adjuvanted gD2 subunit vaccine against genital herpes disease (GHD): results of two clinical efficacy trials [abstract]. In: Craig W, ed. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 2000.
88. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebocontrolled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984; 252:1147-1151.
89. Bryson Y, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl J Med 1983; 308:916-921.
90. Sacks S, Aoki F, Diaz-Mitoma F, Sellors J, Shafran S. Patient-initiated, twice-daily oral famcyclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996; 276:44-49.
91. Spruance S, Tyring S, DeGregorio B, Miller C, Beutner K. A largescale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996; 156:1729-1735.
92. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984; 251:2103-2107.
93. Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982; 2:571-573.
94. Wald A, Benedetti J, Davis G, et al. A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first episode genital herpes infections. Antimicrob Agents Chemother 1994; 38:174-176.
95. Anderson R, May R. Social heterogeneity and sexually transmitted diseases. In: Anderson R, May R, eds. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press, 1991:229-303.
96. Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg (Lond) 1985; 94:365-436.